乳がんリキッドバイオプシー市場レポート：製品・サービス、循環バイオマーカー、エンドユーザー、地域別、2025～2033年

乳がんリキッドバイオプシーの世界市場規模は2024年に1億5,070万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに5億5,340万米ドルに達し、2025～2033年にかけて14.77%の成長率（CAGR）を示すと予測しています。乳がんの有病率の上昇、非侵襲的診断法へのシフト、継続的な技術の進歩、がん研究への投資の急増が、主に市場の成長を牽引しています。

乳がんリキッドバイオプシー市場分析

• 主要市場促進要因：非侵襲的な医療処置に対する需要の高まりとともに、乳がんの有病率が高まっていることが、世界の乳がんリキッドバイオプシー市場の需要を牽引しています。これに加え、迅速な結果、低コスト、最小限の健康リスク、非侵襲性など、リキッドバイオプシー技術に関連する多くの特典に対する消費者の意識の高まりも、市場成長を後押ししています。
• 主要市場動向：乳がん生検やその他の関連医療処置に対する政府と民間の償還施策の増加が、市場に明るい展望をもたらしています。さらに、個別化治療の新たな動向と、がん検出のためのポリメラーゼ連鎖反応（PCR）や次世代シーケンス（NGS）の普及が相まって、今後数年間も世界の乳がんリキッドバイオプシー市場を牽引していくと考えられます。
• 競合情勢：乳がんリキッドバイオプシー市場の著名企業には、Biocept Inc.、Bio-Rad Laboratories Inc.、F. Hoffmann-La Roche AG、Fluxion Biosciences Inc.、Guardant Health Inc.、Illumina Inc.、Menarini Silicon Biosystems（The Menarini Group）、NeoGenomics Laboratories Inc.、Qiagen、Sysmex Europe SE（Sysmex Corporation）などがあります。
• 地理的動向：乳がんリキッドバイオプシー市場予測レポートによると、現在北米が市場全体を支配しています。乳がんは北米で女性が罹患する最も一般的ながんの1つです。症例数の増加は、リキッドバイオプシーのような、より効果的で侵襲性の低い診断ツールの需要を煽っています。
• 課題と機会：リキッドバイオプシー検査の開発と検証にかかる高いコストと規制上のハードルが市場の成長を妨げています。しかし、リキッドバイオプシーは、治療後に微量のがんが残存し、最終的に再発を引き起こす可能性のある微小残存病変（MRD）の検出に用いることができます。この機能は、治療後のモニタリングに大きな機会をもたらします。

乳がんリキッドバイオプシー市場動向

乳がんの有病率の増加

乳がんの世界の有病率の増加は、主要な促進要因の1つです。例えば、世界保健機関（WHO）によると、2022年には世界中で約230万人の女性が乳がんと診断され、約67万人が死亡しました。同様に、全米乳がん財団によると、米国では女性の8人に1人が生涯のうちに乳がんと診断されます。2024年には、推定31万720人の女性と2,800人の男性が浸潤性乳がんと診断されます。乳がんは依然として世界中の女性の間で最も一般的ながんの1つであるため、リキッドバイオプシーのような早期発見・モニタリングソリューションに対する需要が高まっています。これらの要因によって、乳がんリキッドバイオプシー市場シェアは今後数年間で上昇すると予想されます。

早期発見への注力

乳がんの早期発見は患者の予後を著しく改善するが、リキッドバイオプシーは従来型画像診断法よりも早期発見を可能にします。例えば、米国国立医療図書館（National Library of Medicine）が発表した紙製によると、LBは早期段階でのがんの診断、腫瘍の成長と再発の追跡、治療に対する患者の反応の予測において可能性を示しています。また、病気の進行や治療効果を追跡するのに不可欠な継続的モニタリングも可能であり、現代の腫瘍学において不可欠なツールとなっています。これらの要因は、乳がんリキッドバイオプシー市場予測にさらにプラスの影響を与えています。

製品イノベーション

ゲノムシークエンシング、分子生物学、バイオインフォマティクスにおける技術革新は、リキッドバイオプシー技術の感度、特異性、精度を高めています。例えば、2023年11月、DNAシーケンスとアレイベースの技術事業を展開するIllumina社は、ゲノムプロファイリング用の分散型リキッドバイオプシーアッセイの改良版を開発しました。新しいTruSight Oncology 500 ctDNA v2（TSO 500 ctDNA v2）は、血液からの循環腫瘍DNA（ctDNA）の非侵襲的包括的ゲノムプロファイリング（CGP）を可能にする研究用アッセイです。これらの進歩は、がんの早期発見、治療効果のモニタリング、耐性変異の同定に役立ち、臨床現場でのリキッドバイオプシーの採用を促進し、乳がんリキッドバイオプシー市場の成長を後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 世界の乳がんリキッドバイオプシー市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：製品・サービス別

• 試薬キット
• 機器
• サービス

第7章 市場内訳：循環バイオマーカー別

• 循環腫瘍細胞（CTC）
• 遊離DNA（cfDNA）
• 細胞外小胞（EV）
• その他

第8章 市場内訳：エンドユーザー別

• リファレンスラボ
• 病院と医師の検査室
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場内訳：国別

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Guardant Health Inc.
  • Illumina Inc.
  • Menarini Silicon Biosystems（The Menarini Group）
  • NeoGenomics Laboratories Inc.
  • Qiagen
  • Sysmex Europe SE（Sysmex Corporation）

List of Figures

• Figure 1: Global: Breast Cancer Liquid Biopsy Market: Major Drivers and Challenges
• Figure 2: Global: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019-2024
• Figure 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 4: Global: Breast Cancer Liquid Biopsy Market: Breakup by Product Services (in %), 2024
• Figure 5: Global: Breast Cancer Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2024
• Figure 6: Global: Breast Cancer Liquid Biopsy Market: Breakup by End User (in %), 2024
• Figure 7: Global: Breast Cancer Liquid Biopsy Market: Breakup by Region (in %), 2024
• Figure 8: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Breast Cancer Liquid Biopsy (Instruments) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Breast Cancer Liquid Biopsy (Instruments) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Breast Cancer Liquid Biopsy (Services) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Breast Cancer Liquid Biopsy (Services) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Breast Cancer Liquid Biopsy (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Breast Cancer Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: North America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: North America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: United States: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: United States: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Canada: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Canada: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Asia-Pacific: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Asia-Pacific: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: China: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: China: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Japan: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Japan: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: India: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: India: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: South Korea: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: South Korea: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Australia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Australia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Indonesia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Indonesia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Europe: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Europe: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Germany: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Germany: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: France: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: France: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: United Kingdom: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: United Kingdom: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Italy: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Italy: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Spain: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Spain: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Russia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Russia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Latin America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Latin America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Brazil: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Brazil: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Mexico: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Mexico: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Breakup by Country (in %), 2024
• Figure 76: Middle East and Africa: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 77: Global: Breast Cancer Liquid Biopsy Industry: SWOT Analysis
• Figure 78: Global: Breast Cancer Liquid Biopsy Industry: Value Chain Analysis
• Figure 79: Global: Breast Cancer Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Breast Cancer Liquid Biopsy Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Product Services (in Million USD), 2025-2033
• Table 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million USD), 2025-2033
• Table 4: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 5: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Breast Cancer Liquid Biopsy Market: Competitive Structure
• Table 7: Global: Breast Cancer Liquid Biopsy Market: Key Players

The global breast cancer liquid biopsy market size reached USD 150.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 553.4 Million by 2033, exhibiting a growth rate (CAGR) of 14.77% during 2025-2033. The rising prevalence of breast cancer, shift towards non-invasive diagnostic methods, ongoing technological advancements, and surging investment in cancer research, are primarily driving the market's growth.

Breast Cancer Liquid Biopsy Market Analysis:

• Major Market Drivers: The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market demand. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth.
• Key Market Trends: The increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures is creating a positive outlook for the market. Additionally, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
• Competitive Landscape: Some of the prominent breast cancer liquid biopsy market companies include Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation), among many others.
• Geographical Trends: According to the breast cancer liquid biopsy market forecast report, North America currently dominates the overall market. Breast cancer remains one of the most common cancers affecting women in North America. The increasing number of cases fuels the demand for more effective and less invasive diagnostic tools like liquid biopsies.
• Challenges and Opportunities: The high costs of developing and validating liquid biopsy tests and regulatory hurdles are hampering the market's growth. However, liquid biopsies can be used to detect minimal residual disease (MRD), where small amounts of cancer remain after treatment and may eventually cause a recurrence. This capability presents a major opportunity in post-treatment monitoring.

Breast Cancer Liquid Biopsy Market Trends:

Increasing Prevalence of Breast Cancer

The increasing global prevalence of breast cancer is one of the primary drivers. For instance, according to the World Health Organization (WHO), in 2022, nearly 2.3 million women were diagnosed with breast cancer, and approximately 670,000 died worldwide. Similarly, according to the National Breast Cancer Foundation, in the United States, 1 out of every 8 women will be diagnosed with breast cancer during their lifetime. In 2024, an estimated 310,720 women and 2,800 males will be diagnosed with invasive breast cancer. As breast cancer remains one of the most common cancers among women worldwide, the demand for early detection and monitoring solutions, like liquid biopsy, is rising. These factors are expected to propel the breast cancer liquid biopsy market share in the coming years.

Focus on Early Detection

Early detection of breast cancer significantly improves patient outcomes, and liquid biopsy allows for earlier detection than some traditional imaging methods. For instance, according to an article published by the National Library of Medicine, LB has demonstrated potential in diagnosing cancer at an early stage, tracking tumor growth and recurrence, and predicting patient response to therapy. It also enables continuous monitoring, which is essential for tracking disease progression and treatment response, making it an essential tool in modern oncology. These factors further positively influence the breast cancer liquid biopsy market forecast.

Product Innovations

Innovations in genomic sequencing, molecular biology, and bioinformatics are enhancing the sensitivity, specificity, and accuracy of liquid biopsy techniques. For instance, in November 2023, Illumina Inc., a DNA sequencing and array-based technology business, developed an improved version of their distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for non-invasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. These advancements help in early cancer detection, monitoring treatment efficacy, and identifying resistance mutations, which drives the adoption of liquid biopsy in clinical settings, thereby boosting the breast cancer liquid biopsy market growth.

Global Breast Cancer Liquid Biopsy Industry Segmentation:

Breakup by Product Services:

• Reagent Kits
• Instruments
• Services

Currently, reagent kits account for the majority of the global market share

According to the breast cancer liquid biopsy market outlook, the increasing global incidence of breast cancer has heightened the need for better diagnostic, monitoring, and screening tools. As liquid biopsy becomes more commonly used, the demand for reagent kits that support these tests rises proportionally. Moreover, traditional tissue biopsies are invasive and can cause discomfort and complications. Liquid biopsy offers a non-invasive alternative, which is gaining popularity for both diagnostic and treatment monitoring purposes. This shift is a key driver for reagent kits used in liquid biopsy procedures, such as those for detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).

Breakup by Circulating Biomarker:

• Circulating Tumor Cells (CTCs)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs)
• Others

According to the breast cancer liquid biopsy market analysis report, CTCs are cancer cells that have shed from the primary tumor into the bloodstream. The presence of CTCs in the blood correlates with disease stage and prognosis. Higher numbers of CTCs are often associated with advanced cancer and poorer outcomes. Moreover, cfDNA consists of small fragments of DNA released from tumor cells (also referred to as circulating tumor DNA or ctDNA) and other cells into the bloodstream. Moreover, analysis of cfDNA allows for the detection of specific mutations, such as those in the PIK3CA gene, TP53, or ESR1, which can guide treatment choices, especially for targeted therapies. Furthermore, extracellular vesicles (such as exosomes and microvesicles) are small membrane-bound particles released by cells, including cancer cells, into the bloodstream. EVs contain a variety of biomolecules, including proteins, RNA, DNA, and lipids, and can play a role in cell-to-cell communication.

Breakup by End User:

• Reference Laboratories
• Hospitals and Physician Laboratories
• Others

According to the breast cancer liquid biopsy market outlook report, reference labs often have access to the most cutting-edge technologies in liquid biopsy, including next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Their advanced infrastructure attracts demand from hospitals and physician labs that do not have these capabilities. Moreover, large hospitals, especially those with dedicated oncology centers, have a high volume of breast cancer patients requiring regular monitoring. Liquid biopsy offers a less invasive, faster alternative to traditional tissue biopsies for diagnosis, treatment monitoring, and recurrence detection. Furthermore, physical labs are often the first point of care for breast cancer screening. Liquid biopsies provide a more accessible and less invasive option for patients at high risk of breast cancer, allowing for earlier detection and intervention.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the global market.

According to the breast cancer liquid biopsy market statistics, breast cancer remains one of the most common cancers among women in North America, driving demand for improved diagnostic tools. Moreover, liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, which can be painful, risky, and difficult to perform, especially in advanced cancer cases. As a simple blood test, liquid biopsy is more appealing to patients, contributing to its growing adoption. Besides this, advances in liquid biopsy technologies, including next-generation sequencing (NGS), PCR-based methods, and improved ctDNA and CTC (circulating tumor cells) detection platforms, have significantly increased the accuracy and sensitivity of these tests. These innovations are driving wider clinical adoption of liquid biopsy for breast cancer diagnosis and monitoring.

Competitive Landscape:

The breast cancer liquid biopsy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Biocept Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche AG
• Fluxion Biosciences Inc.
• Guardant Health Inc.
• Illumina Inc.
• Menarini Silicon Biosystems (The Menarini Group)
• NeoGenomics Laboratories Inc.
• Qiagen
• Sysmex Europe SE (Sysmex Corporation)

Key Questions Answered in This Report

• 1.What was the size of the global breast cancer liquid biopsy market in 2024?
• 2.What is the expected growth rate of the global breast cancer liquid biopsy market during 2025-2033?
• 3.What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
• 4.What are the key factors driving the global breast cancer liquid biopsy market?
• 5.What is the breakup of the global breast cancer liquid biopsy market based on the product services?
• 6.What are the key regions in the global breast cancer liquid biopsy market?
• 7.Who are the key players/companies in the global breast cancer liquid biopsy market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Breast Cancer Liquid Biopsy Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Services

• 6.1 Reagent Kits
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker

• 7.1 Circulating Tumor Cells (CTCs)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cell-Free DNA (cfDNA)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Extracellular Vesicles (EVs)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Reference Laboratories
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Hospitals and Physician Laboratories
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Biocept Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bio-Rad Laboratories Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 F. Hoffmann-La Roche AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Fluxion Biosciences Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Guardant Health Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Illumina Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Menarini Silicon Biosystems (The Menarini Group)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 NeoGenomics Laboratories Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Qiagen
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Sysmex Europe SE (Sysmex Corporation)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio